Porda Havas assisted Sirnaomics Ltd. (2257.HK) to successfully land in Hong Kong capital market
Latest Update:
30 th December, 2021

December 30, 2021Sirnaomics Ltd. ("Sirnaomics" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 2257.HK), the first clinical stage with significant operations in both China and the United States An RNA Therapeutics biopharmaceutical company, and the first RNAi therapeutics company to achieve positive Phase IIa clinical results in oncology, was officially listed on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEx”) today and began trading.
 
Sirnaomics' global offering totals 7,540,000 shares, and the final offer price per offer share is HK$65.90. After deducting the underwriting fees and expenses paid and payable in connection with the Global Offering, the Company's net proceeds from the Global Offering are estimated to be approximately HK$395.7 million. The Company's Hong Kong Public Offering was slightly over-subscribed, with valid applications received at approximately 5.68 times the total number of Offer Shares initially available for subscription, and the International Offering was also slightly over-subscribed by approximately 1.22 times.

Sirnaomics currently has more than ten candidate products in its product line, which are suitable for a series of therapeutic indications such as various rare diseases and diseases with a large number of patients, covering fields such as tumor, fibrosis, medical aesthetics, antiviral, cardiovascular disease, and metabolic disease. Product candidates currently span all stages from preclinical studies to IND-ready studies to Phase I and Phase II clinical studies, creating a rich portfolio of product candidates and expanding timelines. Sirnaomics' proprietary delivery platform based on RNA therapy for drug delivery is the foundation of the company's product pipeline development, and the related proprietary PNP and novel GalNAc drug delivery platforms have advantages over traditional delivery platforms. The company believes its highly innovative RNAi delivery platform makes Sirnaomics unique. The company's PNP delivery platform allows for the delivery of siRNA and mRNA to diseased cells via local or systemic administration with the significant advantages of low toxicity, ease of manufacture and access to target organs, and several cell types. Results from the company's Phase IIa oncology clinical trial validated the efficacy of its PNP delivery platform and the therapeutic targeting of isSCC, enabling the company to expand its product pipeline and use the same PNP delivery platform to advance its development of related pipeline products. The company's core product candidate, STP705, as well as other clinical-stage product candidates, STP707, and at least eight other preclinical product candidates utilize the PNP delivery platform. RNAimmune, a controlled subsidiary of Sirnaomics, also applies its PNP delivery platform and related proprietary delivery platforms based on peptide-lipid nanoparticles (PLNPs) to develop mRNA-based therapeutics and vaccines.
 
Dr. Lu Yang, Founder, Chairman of the Board, President and CEO of Sirnaomics, said: "Today is a major milestone in the development of Sirnaomics. The company's successful listing on the Hong Kong Stock Exchange reflects global investors' interest in our strategic model, growth potential, Proprietary and novel drug delivery platform, rich product pipeline and deep affirmation of experienced management team. We are proud of this and sincerely thank our investors for their trust and support in Sirnaomics. We will strive to become a fully integrated company The international biopharmaceutical company, relying on the company's deep experience in RNA therapeutics and multiple novel delivery platform technologies, will continue to vigorously promote the development of innovative therapeutic modalities to treat a wide range of diseases in order to maximize the potential of clinical product candidates and provide global health benefits. Rapidly discover, develop and commercialize a range of transformative therapies and vaccines for patients with a variety of rare diseases."

About Sirnaomics Ltd.
Sirnaomics Ltd. ("Sirnaomics" or the "Company"; stock code: 2257.HK) is an RNA therapy biopharmaceutical company with product candidates in preclinical and clinical stages, focusing on the exploration and development of innovative drugs for the treatment of existing medical Indications for demand and huge market opportunities. The company is the first clinical-stage RNA therapy biopharmaceutical company with significant market positions in both China and the United States, and the first company to achieve positive Phase IIa clinical results in oncology for the RNAi therapy of its core product STP705.

Latest Update:
30 th December, 2021